Author highlights Novo Nordisk's oral Wegovy pill hitting 20,371 prescriptions in week two, up nearly 500% week-over-week, far outpacing Eli Lilly's Zepbound and Novo's own injectable Wegovy launch.
NVO — LONG The author argues Novo Nordisk's oral Wegovy pill is off to a very strong start, hitting 20,371 prescriptions in just its second week, up nearly 500% week-over-week from 4,289 in week one. This compares favorably to Eli Lilly's Zepbound at about 10,000 scripts in week two and Novo's original injectable Wegovy at barely 1,000, suggesting strong commercial momentum for the oral GLP-1 franchise. The author frames this as an amazing start, implying a bullish read on NVO.
In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge.
This Reddit post, published January 23, 2026, features u/SelfMastery__ discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/SelfMastery__ · Tickers: NVO